Global Salivary Gland Cancer Treatment Market - 2022-2029

Global Salivary Gland Cancer Treatment Market - 2022-2029

Market Overview

The global salivary gland cancer treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Salivary gland cancer is rare cancer that develops in the tissue of the salivary glands. These glands control the production of saliva. A lump or difficulty swallowing are indications of this malignancy. Most salivary gland cancers begin in the parotid glands and are benign. Biopsy or imaging tests such as an MRI, CT scan, or PET scan diagnose this illness. Salivary gland tumors are often treated with surgery to remove the tumor. Additional treatments, such as radiation therapy and chemotherapy, may be required for people with salivary gland cancer.

Market Dynamics

Increasing clinical trials and product launches by the market players are expected to drive market growth.

The Ministry of Health, Labour and Welfare (MHLW) approved Chugai Pharmaceutical Co., Ltd.'s anti-HER2 humanized monoclonal antibody Herceptin Injection 60 and 150 [generic name: trastuzumab] for the additional indication of advanced or recurrent HER2-positive salivary gland cancer not amenable to curative resection on November 25, 2021. The MHLW approved orphan drug classification for this indication on March 11, 2021. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The high cost of treatment, lack of awareness about the disorder, side effects caused by the drugs and limited availability of required healthcare facilities are factors the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the healthcare industry. The oral mucosal and salivary gland cells are known targets for directly replicating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of the virus in saliva is a source of transmission of the infection. The researchers suspect that SARS-CoV-2 released from the salivary glands may inhibit the production of antibodies and, as a result, increase the risk of relapse or reinfection. They also could limit the long-term effects of vaccines. Moreover, there was a delay in diagnosis, surgery, chemotherapy, radiation therapies, and oncology follow-ups conducted by telemedicine rather than in-person appointments during this difficult period.

Moreover, traveling to clinics can increase social contact, making these patients more prone to SAR-CoV-2 infection than the general population, which can better quarantine at home. As a result of the COVID-19 pandemics' reduced access to care, the work-up process has slowed even more. There has been a significant decrease in the number of urgent referrals. Furthermore, because of the pandemics and rapid progression in the months following its emergence, physicians and hospitals quickly respond to the crisis and establish a recovery plan to address patient diagnosis and management challenges.

Segment Analysis

Surgery segment is expected to hold the largest market share in salivary gland cancer treatment market

The surgery segment is expected to dominate in 2021. Surgery is usually the first treatment option for nearly everyone diagnosed with salivary gland cancer. The goal of surgery is to remove as much of the tumor as possible while keeping the margins as clean as possible. It signifies that no trace of cancer is identified in the removed healthy tissue. Cancer's location and extent determine the type and scope of surgery.

Moreover, many types of surgery are used to treat salivary gland cancer—for instance, Parotidectomy, Endoscopic surgery, Neck dissection, and Reconstructive surgery. Therefore, it has increased the demand for the treatment. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global salivary gland cancer treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of salivary gland cancer, the rising geriatric population, advancements in the treatment, well-established infrastructure and product launches by the key players are some factors the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, Salivary gland cancers are not very common, making up 6% to 8% of all head and neck cancers in the United States. There are about 2,000 to 2,500 cases in the US each year. They occur at about 3 cases per 100,000 people per year in the Western world.

Moreover, using drugs to kill cancer cells is known as systemic treatment. This sort of drug is injected into the bloodstream to reach cancer cells all over the body. A medical oncologist, a clinician, specializing in using medications to treat cancer, usually prescribes systemic therapy. The benefits of systemic therapy for salivary gland cancer are still being researched, and this sort of treatment is being tested in clinical studies. In addition, Systemic therapy is most commonly used to treat later-stage cancer or to reduce symptoms in patients with salivary gland cancer. Some medications are being tested in clinical trials to see if they can treat cancer at an earlier stage or be paired with radiation therapy to see if it works. Therefore, it has increased the demand for the treatment of salivary gland cancer. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the salivary gland cancer treatment market are Bristol-Myers Squibb Company, LGM PHARMA, Pfizer Inc., Bedford Laboratories, Baxter, sanofi-aventis U.S. LLC, Pierre Fabre Médicament, Antares Pharma, Inc., CMS Group, Sandoz Inc.

Bristol Myers Squibb:

Overview:

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company. It is headquartered in New York City. The company has advancements in oncology, hematology, immunology and cardiovascular disease. It is dedicated to helping patients prevail over serious diseases through its diverse and promising pipelines and new scientific platforms. Bristol Myers Squibb is at the forefront of oncology with an extensive portfolio of investigational compounds and approved medicines. Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs and is a subsidiary of Bristol Myers Squibb.

­Product Portfolio:

PLATINOL (cisplatin for injection): Platinol (cisplatin) for Injection is a cancer medication used together with other medications to treat various types of cancers.

MyLab™9V

Why Purchase the Report?

Visualize the composition of the salivary gland cancer treatment market segmentation by type, diagnosis, treatment, end user, distribution channel and region highlighting the key commercial assets and players.

Identify commercial opportunities in salivary gland cancer treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of salivary gland cancer treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global salivary gland cancer treatment market report would provide an access to an approx. 45+market data table, 40+figures and 200 pages.